GPCR Structure Therapeutics Inc. American
Company Analysis
Latest News
🟢 Structure Therapeutics is trading 4.1% up today as biotech sector rallies
Structure Therapeutics is trading 4.1% up at $50.32 as biotech shares continue to rally amid a broader risk-on environment. • The sector backdrop remains...
Structure Therapeutics Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
For the second quarter of 2026, analysts expect Structure Therapeutics to report a net loss of $0.39 per share on zero revenue, while the current stock price...
🔴 Structure Therapeutics is trading 4.3% down today in a consolidation move following a sharp biotech-led rebound
Structure Therapeutics is trading at $47.14 (down 4.3%) in a consolidation move following a sharp two-day biotech-led rally. • The stock previously climbed to...
🟢 Structure Therapeutics is trading 4.1% up today amid a broader biotech and market rally
Structure Therapeutics is trading 4.1% higher at $51.50 in pre-market, continuing a strong rebound driven by a broader biotech rally and improving risk...
🟢 Structure Therapeutics is trading 4.4% up today amid a broader biotech and market rally
Structure Therapeutics is trading 4.4% up at $49.45 as part of a broader risk-on move across the biotech sector and major U.S. indices. • The stock is...
🟢 Structure Therapeutics is trading 5.5% up today amid broader market strength and no company-specific news
Structure Therapeutics is trading at $49.94 (+5.47%) in pre-market as the stock gains alongside a broader market rally despite no clear company-specific...
🔴 Structure Therapeutics is trading 4.5% down today amid broader sector consolidation and risk-off pressure
Structure Therapeutics is trading at $46.51 (-4.48%) in pre-market amid broader sector consolidation and risk-off pressure, as no clear company-specific...
🟢 Structure Therapeutics rises 4.4% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🟢 Structure Therapeutics is trading 4.1% up today on strong Phase 2b data for oral GLP-1 candidate
Structure Therapeutics is trading 4.1% up now at $48.91 as investors continue to react to strong Phase 2b data for its oral GLP-1 obesity candidate,...
🟢 Structure Therapeutics is trading 4.2% up today on continued momentum from positive GLP-1 trial data
Structure Therapeutics is trading 4.2% up at $48.97 in pre-market action, resuming its upward trend following a brief pullback on July 20. • The stock's...
🔴 Structure Therapeutics is trading 4.2% down today on profit-taking after recent GLP-1 rally
Structure Therapeutics is trading at $46.45, down 4.2% today, as the stock undergoes profit-taking following a sharp multi-day rally driven by positive...
🟢 Structure Therapeutics Soars 4.6% on Positive GLP-1 Phase 2b Data and Strong Institutional Interest Amid Biotech Weakness
Structure Therapeutics is trading at $48.14 (+4.58%) today, driven by recent positive Phase 2b trial results for its oral GLP-1 obesity drug aleniglipron,...
🟢 Structure Therapeutics is trading 4.3% up today amid easing insider-selling concerns
Structure Therapeutics is trading at $48.00 (4.3%) up in after-hours trading as investors reassess recent volatility tied to insider selling and...
🔴 Structure Therapeutics is trading 4.2% down today amid CSO's recent share sales and profit-taking
Structure Therapeutics is trading 4.2% down at $47.52 as investors react to recent insider selling and engage in profit-taking following a major rally tied to...
🟢 Structure Therapeutics is trading 4.9% up today, rebounding after profit taking following positive obesity drug data
Structure Therapeutics is trading 4.9% higher at $54.14 in pre-market action, staging a partial recovery after two consecutive sessions of profit taking. •...
🔴 Structure Therapeutics is trading 4.1% down today on continued profit-taking after obesity-drug rally
Structure Therapeutics is trading 4.1% down now at $51.19 as investors continue to lock in gains after a powerful rally driven by bullish oral GLP-1 obesity...
🔴 Structure Therapeutics is trading 4.2% down today on profit-taking after obesity-drug rally and acquisition rumors
Structure Therapeutics is trading 4.2% down at $52.84 as investors take profits following a sharp multi-month rally driven by positive oral obesity-drug data...
🔴 Structure Therapeutics is trading 8.2% down today as investors take profits following a strong obesity-pill rally
Structure Therapeutics is trading 8.2% down at $50.64 in pre-market, pulling back after a multi-month rally fueled by positive obesity-pill data and...
🔴 GPCR is trading 4.4% down today amid biotech selloff and analyst price target cut
GPCR is trading 4.4% down at $54.16 amid broader weakness in risk assets and cautious sentiment across the biotechnology sector. • H.C. Wainwright recently...